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a b s t r a c t
The effectiveness and mechanisms of psychotherapies for posttraumatic stress disorder (PTSD) in
treating sleep problems is of interest. This study compared the effects of a trauma-focused and a non-
trauma-focused psychotherapy on sleep, to investigate whether 1) sleep improves with psychotherapy
for PTSD; 2) the degree of sleep improvement depends on whether the intervention is trauma or non-
trauma-focused; 3) the memory-updating procedure in cognitive therapy for PTSD (CT-PTSD) is asso-
ciated with sleep improvements; 4) initial sleep duration affects PTSD treatment outcome; and 5) which
symptom changes are associated with sleep duration improvements. Self-reported sleep was assessed
during a randomized controlled trial (Ehlers et al., 2014) comparing CT-PTSD (delivered weekly or
intensively over 7-days) with emotion-focused supportive therapy, and a waitlist. Sleep duration was
reported daily in sleep diaries during intensive CT-PTSD. CT-PTSD led to greater increases in sleep
duration (55.2 min) and reductions in insomnia symptoms and nightmares than supportive therapy and
the waitlist. In intensive CT-PTSD, sleep duration improved within 7 days, and sleep diaries indicated a
40-min sleep duration increase after updating trauma memories. Initial sleep duration was not related to
CT-PTSD treatment outcome when initial PTSD symptom severity was controlled. The results suggest
that trauma-focused psychotherapy for PTSD is more effective than nontrauma-focused therapy in
improving self-reported sleep, and that CT-PTSD can still be effective in the presence of reduced sleep
duration.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Sleep disturbances, such as difﬁculty falling and staying asleep
and nightmares are two of the diagnostic symptoms of post-
traumatic stress disorder (PTSD) (American Psychiatric Association,
2013). Sleep problems in PTSD include reduced self-reported and
objective sleep duration and lower reported sleep quality (for re-
view see Cox & Olatunji, 2016) and up to 60% of people with PTSD
and insomnia complaints also meet criteria for an insomnia
disorder (Ohayon & Shapiro, 2000).
Trauma-focused psychological therapies are the ﬁrst-line rec-
ommended treatments for individuals suffering from PTSD,
including when comorbid insomnia is present. It is therefore
important to understand the effects of trauma-focused PTSD
treatments on sleep outcomes in order to maximize PTSD treat-
ment efﬁcacy. Only a small number of studies have investigated the
effects of trauma-focused PTSD therapies on sleep outcomes (e.g.,
Belleville, Guay, & Marchand, 2011; Brownlow et al., 2016;
Galovski, Monson, Bruce, & Resick, 2009; Galovski et al., 2016;
Gutner, Casement, Gilbert, & Resick, 2013; Levrier, Marchand,
Belleville, Dominic, & Guay, 2016; Lommen et al., 2015; Nishith
et al., 2003; Raboni, Tuﬁk, & Suchecki, 2006; Zayfert & DeViva,
2004). Improvement in sleep has been found for prolonged expo-
sure (PE) and cognitive processing therapy (CPT) for PTSD
(Brownlow et al., 2016; Galovski et al., 2016, 2009; Gutner et al.,
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2013), eye-movement desensitization and reprocessing therapy
(Raboni et al., 2006), other cognitive behavioural therapies
(Belleville et al., 2011; Levrier et al., 2016; Nishith et al., 2003;
Zayfert & DeViva, 2004), and cognitive therapy for PTSD (CT-
PTSD) (Lommen et al., 2015). Direct comparisons of two evidence-
based, trauma-focused PTSD therapies, CPT and PE, found no dif-
ferences in sleep improvement between treatments (Galovski et al.,
2009; Gutner et al., 2013).
However, studies have also found that despite improvements in
self-reported sleep duration and/or quality (Belleville et al., 2011;
Galovski et al., 2009; Gutner et al., 2013; Lommen et al., 2015),
nightmares (e.g., Gutner et al., 2013; Levrier et al., 2016), and
insomnia symptoms (e.g., Gutner et al., 2013), sleep difﬁculties are
commonly residual after PTSD therapy (Belleville et al., 2011;
Galovski et al., 2016, 2009; Gutner et al., 2013), including in those
who have recovered from PTSD (Zayfert & DeViva, 2004).
It would therefore be important to investigate further which
PTSD therapies, and which aspects of PTSD therapy, best promote
sleep improvements, and whether sleep problems are residual to
the same extent across different psychotherapies for PTSD. To our
knowledge, no study has yet compared the effects of trauma and
nontrauma-focused psychotherapy for PTSD on sleep, in adults. If
trauma-focused therapy has superior effects on sleep compared to
nontrauma-focused therapy, this may suggest that the focus on
trauma memories and their meaning in these treatments may
contribute to sleep improvements. It is also of interest to explore
whether sleep improvement coincides with certain procedures in
treatment that aim to change the “here and now” quality of trauma
memories, such as the updating memories procedure in CT-PTSD
(Ehlers & Clark, 2000). In this procedure, the individually most
upsetting moments in memory are linked to less threatening
meanings that the patient and therapist have identiﬁed from the
course of events (e.g., “I did not die”) or through cognitive
restructuring (e.g., “I could not have prevented the trauma even if I
had acted differently”).
Furthermore, few studies have investigated which symptom
changes are associated with sleep improvements with trauma-
focused PTSD therapy (e.g., Lommen et al., 2015). Understanding
whether treatment changes symptoms that have been associated
with sleep disturbances in PTSD, such as arousal (see Sinha, 2016)
and trauma-related nightmares (e.g., Woodward, Arsenault,
Murray, & Bliwise, 2000), would be informative.
Finally, research demonstrating the importance of sleep in
learning and memory, emotional processing (Diekelmann, Biggel,
Rasch, & Born, 2012; Wagner, Hallschmid, Rasch, & Born, 2006;
Walker & van der Helm, 2009; Yoo, Hu, Gujar, Jolesz, & Walker,
2007), and retention and generalization of fear extinction
learning (Kleim et al., 2013; Pace-Schott, Verga, Bennett,& Spencer,
2012) has contributed to concerns that reduced sleep duration may
have a detrimental effect on response to psychological PTSD
treatments. Many of the trauma-focused treatments for PTSD
involve some form of exposure to trauma memories and reminders
(Schnyder et al., 2017), and it is possible that reduced sleep duration
may interfere with the effects of exposure through impairing
retention of fear extinction learning. Poor sleep may also interfere
by impacting an individual's ability to retain learning from the
treatment session through reducing concentration and attention in
therapy, or interfering with consolidation of new information from
the session, such as updated information and meanings in the
trauma memory. There is also some evidence that poor sleep
quality predicts a slower response to PTSD treatment, in people
with PTSD and comorbid major depression (Lommen et al., 2015).
However, recent studies have also found that nightmares did not
impact the efﬁciency of CBT for PTSD (Levrier et al., 2016), and that
while sleep-directed hypnosis before CPT for PTSD improved sleep
more than a control condition, it did not lead to greater improve-
ments in PTSD symptoms after CPT (Galovski et al., 2016), and thus
initial evidence is so far inconclusive. Further research is needed
into the effects of reduced sleep duration on PTSD treatment
outcomes.
1.1. Study aims
The primary aim of this study was to compare the effects of a
trauma-focused and a nontrauma-focused psychotherapy for
PTSD on self-reported sleep, in a randomised controlled trial
design, in a secondary analysis of a clinical trial by Ehlers and
colleagues (2014). This trial compared trauma-focused CT-PTSD
(Ehlers & Clark, 2000; Ehlers, Clark, Hackmann, McManus, &
Fennell, 2005) to emotion-focused supportive therapy, an active
nontrauma-focused treatment, and a waitlist control. Both psy-
chotherapies (cognitive and supportive therapy) led to greater
changes in PTSD symptoms than the waitlist, and CT-PTSD lead to
greater improvements in PTSD symptoms than supportive therapy
(see Ehlers et al., 2014 for full results). For the sleep study pre-
sented here, sleep duration was the primary outcome measure as
it was the most regularly available sleep outcome. Additional
analyses included sleep quality and insomnia symptoms that were
assessed before and after treatment.
Speciﬁcally, the present study investigated whether 1) trauma-
focused (CT-PTSD) and nontrauma-focused psychological treat-
ment (supportive therapy) lead to greater improvement in sleep
than the waitlist control, and 2) the degree of sleep improvement
depends on whether the intervention is trauma or nontrauma-
focused. If psychotherapy generally improves sleep, both CT-
PTSD and supportive therapy would be expected to lead to
greater improvement in sleep than a waitlist. If trauma-focused
therapy is important for improving sleep with PTSD treatment,
then CT-PTSD would be expected to lead to greater improvements
in sleep than supportive therapy, which focuses on present feel-
ings and problems, rather than trauma memories and their
meanings.
The study further investigated 3) whether the memory-
updating procedure in CT-PTSD was associated with sleep im-
provements. To do this, the study compared two versions of CT-
PTSD, a standard weekly version and an intensive version, in
which the interventions which promote memory-updating were
delivered over ﬁve to seven working days, compared to three
months for standard CT-PTSD. This enabled investigation of
whether sleep improvements coincided with interventions that
facilitate memory-updating: First, by comparing standard and
intensive treatment at a time point when memory-updating had
taken place for the intensive, but not the standard weekly CT-PTSD
group; and second, by analysing daily sleep diaries completed by
the intensive CT-PTSD group, to compare sleep directly before and
after memory-updating. If linking the worst moments in trauma
memories with less threatening meanings promotes sleep im-
provements with CT-PTSD, then it would be expected that sleep
would signiﬁcantly improve after the memory-updating procedure
in therapy.
Next, 4) the effect of sleep duration on PTSD treatment outcome
was also investigated. If reduced initial sleep duration interferes
with treatment outcome, it would be expected that lower sleep
duration at pre-treatment would predict more severe PTSD
symptoms at post-treatment.
Finally, 5) in patients who received CT-PTSD, associations be-
tween improvement in sleep duration and symptoms hypothesised
to be related to sleep improvements were explored. These were
reductions in nightmares, hyperarousal and anxiety about going to
bed.
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2. Methods
2.1. Participants
Participants were out-patients with PTSD (N ¼ 121) who
participated in a randomized controlled trial comparing psycho-
logical treatments for PTSD and a waitlist condition (Ehlers et al.,
2014, ISRCTN: 48524925). The sample comprised 71 women and
50 men (aged 18e65) who met diagnostic criteria for PTSD, as
determined by the Structured Clinical Interview for DSM-IV (First,
Gibbon, Spitzer, & Williams, 1996). Participants were included if
PTSD was their primary diagnosis, and their current intrusive
memories were linked to one or two traumas in adulthood. Details
of trauma type and demographics are shown in Table 1 (see Ehlers
et al., 2014, for further sample details).
2.2. Treatment conditions
Participants were randomly allocated to one of four conditions:
(1) trauma-focused cognitive therapy for PTSD (CT-PTSD), delivered
over 12 weeks (N ¼ 31); (2) intensive CT-PTSD (N ¼ 30) delivered
over ﬁve to seven days; (3) emotion focused supportive therapy,
delivered over 12 weeks (N ¼ 30); or (4) a 14-week waitlist
(N ¼ 30). By the 14-week assessment patients in all treatment
conditions had received equivalent therapist input of up to 20 hours
of therapy. The therapy conditions are outlined below (see Ehlers
et al., 2014, for full details).
2.2.1. Cognitive therapy for PTSD (CT-PTSD; Ehlers et al., 2005)
This is a trauma-focused therapy, which follows Ehlers and
Clark's model of PTSD (Ehlers& Clark, 2000). The treatment aims to
reduce the patient's sense of current threat by changing problem-
atic meanings of the trauma and its consequences, elaborating and
updating the memories of the trauma with information that gives
them a less threatening meaning at present, discriminating triggers
of intrusive memories, and changing behaviours and cognitive
processes that maintain PTSD, such as rumination and safety be-
haviours. For details of procedures see: http://oxcadat.psy.ox.ac.uk/
downloads/CT-PTSD%20Treatment%20Procedures.pdf/view. Sleep
was not directly targeted. CT-PTSD was delivered in 12 weekly
sessions over threemonths (standard CT) or as an intensive therapy
(intensive CT), whichwas delivered daily over ﬁve to sevenworking
days and two shorter sessions one week and one month later.
2.2.2. Emotion-focused supportive therapy (EST)
This non-directive treatment focuses on the patient's emotions
rather than cognitions. After normalizing PTSD symptoms, the
therapist gave the rationale that the trauma had left the patient
with unprocessed emotions and that therapy would provide them
with support and a safe context to address their unresolved emo-
tions. Patients could freely choose what problems to discuss in the
session, including any aspect of the trauma. Therapists helped pa-
tients clarify their emotions and solve problems. EST was delivered
in 12 weekly sessions over 3 months.
2.2.3. 14 week waitlist
Patients waited for 14 weeks before random allocation to either
weekly (n ¼ 13) or intensive CT-PTSD (n ¼ 11).
2.3. Measures
Self-reported PTSD symptom severity (excluding sleep) and
sleep duration were assessed at baseline (pre-treatment/wait), 6
weeks and 14weeks (post-treatment/wait). Treatment groupswere
also assessed at 3 weeks, and at the 27- and 40-week follow-ups.
Assessments with an independent rater unaware of allocation
were conducted at baseline,14weeks, 27 and 40weeks. Other sleep
outcomes (insomnia symptoms, nightmares and sleep quality)
were assessed at baseline and 14 weeks. Sleep quality and sleep
duration (total time spent asleep) are two of a number of sleep
outcomes recommended in the subjective assessment of sleep
(Buysse, Ancoli-Israel, Edinger, Lichstein, & Morin, 2006), and
provide information about the subjective experience of sleep.
2.3.1. Main measures completed by all groups
Patients in the treatment groups completed a PTSD symptom
measure and reported sleep duration at baseline, 3, 6, 14, 27 and 40
weeks, and those in the waitlist group at baseline and weeks 6 and
14.
2.3.1.1. PTSD symptoms. The main PTSD symptom measure for the
purposes of the present study was the Posttraumatic Diagnostic
Scale (PDS) (Foa, Cashman, Jaycox, & Perry, 1997), a self-report
questionnaire measuring the overall severity of 17 PTSD symp-
toms speciﬁed in the DSM-IV. The PDS has shown good reliability
and concurrent validity with other PTSD measures. Sum scores
range from 0 to 51. In the present study, the results of independent
assessments with the Clinician-administered PTSD Scale (CAPS) for
DSM-IV (Blake et al., 1995) showed identical results to the PDS for
outcome, but the CAPS was given less frequently than the PDS (see
Ehlers et al., 2014), and so PDS-assessed PTSD symptom severity is
reported. The PDS sleep item (‘having trouble falling or staying
asleep’), was omitted for the purposes of the present analyses, and
the PTSD severity score was based on the remaining 16 items.
2.3.1.2. Self-reported sleep duration. Patients reported how many
hours of sleep they had had on average per night over the past
week. This was used as the primary sleep outcome measure in this
study, as duration was available at every assessment point, and in
the sleep diary (see below), whereas the additional sleep measures
(with the exception of the PDS insomnia item) were only available
at initial assessment and 14-weeks.
2.3.2. Additional measures completed by all groups
To explore other aspects of sleep and potentially associated
processes, further measures were taken at baseline and 14 weeks.
2.3.2.1. Self-reported sleep quality. Patients rated their overall sleep
quality over the past week (‘overall, howwell did you sleep?’ rated on
a scale from 0 'not at all well' to 100 'very well'). Two participants in
each group had missing data because the measure was introduced
with delay.
2.3.2.2. Insomnia symptoms. Severity of sleep problems was also
assessed with the CAPS insomnia item (‘problems falling or staying
asleep’; frequency plus intensity rating, each measured on a scale
from 0 to 4), at initial assessment and 14weeks. For comparison, we
also analysed the PDS insomnia item 13 (‘having trouble falling or
staying asleep’; frequency rated on a scale from 0 ‘not at all’ to 3 ‘5 or
more times a week’) at these time points. The percentage of patients
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meeting the clinical cut-off for the CAPS insomnia item (frequency
at least 1, and intensity at least 2 ’30 e 90 min loss of sleep’) at initial
assessment and 14 weeks, was also calculated.
2.3.2.3. Associated symptoms: arousal, nightmares and pre-bed
anxiety. Symptoms that may be associated with treatment effects
on sleep duration included nightmares (CAPS and PDS item), hy-
perarousal symptoms, excluding difﬁculty falling and staying
asleep (mean of CAPS hyperarousal items, and of PDS hyperarousal
items: 14, 15, 16 and 17), and patient ratings of feeling anxious
about going to bed (on a scale from 0 'not at all' to 100 'very much').
2.3.3. Measures completed by intensive cognitive therapy patients
only
2.3.3.1. Sleep diary (daily reported sleep duration). Participants
receiving intensive CT-PTSD (including those initially allocated to
waitlist; N ¼ 32) reported their sleep duration in a sleep diary each
morning for 6 weeks in total; two weeks pre-treatment, two weeks
during the intensive treatment phase (one week) and the following
week (one week), and two weeks before the 6-week assessment.
Participants reported how many hours and minutes they had slept
the previous night. Weekly self-reported sleep duration (from the
questionnaires) correlated with the mean sleep duration reported
in the diary at pre-treatment (r¼ 0.85, N¼ 32), and post-treatment
(r ¼ 0.78, n ¼ 26).
2.4. Data analysis
Analyses were conducted using SPSS version 22. To test whether
psychological treatments lead to improvements in sleep (Question
1), an analysis of covariance (ANCOVA) compared reported sleep
duration at 6 and 14 weeks, with the between-subject factor ‘con-
dition’ (CT, EST, wait) and the within-subject factor ‘time’, and the
covariate baseline sleep duration. Overall effects of condition are
reported, as well as adjusted mean differences and 95% conﬁdence
intervals (CI) for differences between the treatment conditions and
waitlist. Effect sizes (ES) are reported as partial h2, with small
ES  0.01; medium  0.06; and large  0.14. Additional ANCOVAs
compared the other sleep measures taken at baseline and 14 weeks
(sleep quality, insomnia items from the CAPS and PDS) with be-
tween factor ‘condition’ (CT, EST, wait), controlling for baseline
severity. Changes in the proportion of patients meeting the clinical
cut-off on the CAPS insomnia item before and after therapy were
compared with related-samples McNemar tests.
To test whether cognitive therapy leads to greater improvement
in sleep than supportive therapy (Question 2), an ANCOVA
compared reported sleep duration at 6, 14, 27 and 40 weeks, with
the between factor ‘condition’ (CT, EST) and the within-subject
factor ‘time’, controlling for baseline sleep duration. For this anal-
ysis, the treatment groups (CT, EST) included participants that were
initially allocated to the waitlist. Treatment group differences on
additional sleep measures (sleep quality, insomnia symptoms;
CAPS and PDS) measured at 14 weeks were analysed with further
ANCOVAs, controlling for baseline severity.
For comparison, parallel analyses are reported for PTSD severity
excluding sleep (PDS, see Ehlers et al., 2014, for comprehensive
analyses of PTSD and other outcome measures).
Question 3 was analysed in three steps. First, an ANCOVA
compared sleep duration in intensive and standard CT at 3 weeks,
controlling for baseline sleep duration. By the 3-week assessment,
the intensive, but not the standard CT group, had completed the
memory-updating interventions. This analysis included the
Table 1
Demographic information and trauma characteristics by treatment condition.
Demographics Intensive Cognitive
Therapy (N ¼ 30)
Standard Cognitive
Therapy (N ¼ 31)
Supportive Therapy
(N ¼ 30)
Waitlist (N ¼ 30)
M SD N % M SD N % M SD N % M SD N %
Sex Female 18 60.0 18 58.1 17 56.7 18 60
Male 12 40.0 13 43.9 13 43.4 12 40
Ethnic Group Caucasian 22 73.3 20 64.5 22 73.3 21 70
Ethnic Minority 8 26.7 11 35.5 8 26.7 9 30
Age (Years) 39.7 12.4 41.5 11.7 37.8 9.9 36.8 10.5
Traumas M SD N % M SD N % M SD N % M SD N %
Type of Main Traumatic Event Interpersonal Violence1 12 40.0 12 38.7 11 36.7 10 33.3
Accidents/Disaster 11 36.7 11 22.6 14 10.0 10 33.3
Death/Harm to Others 2 6.7 1 3.2 2 6.7 4 13.3
Other 5 16.7 7 22.6 3 10.0 6 20
Time since Main Traumatic Event 3 months - 1 year 10 33.3 14 45.2 8 27.8 14 46.7
1 to 2 years 10 33.3 5 16.1 7 24.1 6 20
2 to 4 years 7 23.3 11 35.5 8 27.6 3 10
More than 4 years 3 10.0 1 3.2 6 20.7 7 23.3
History of Other Trauma Yes 22 63.3 21 67.7 23 76.7 20 66.7
No 8 26.7 10 32.3 7 23.3 10 33.3
Reported History of Childhood Abuse Yes 5 16.7 2 6.5 4 13.3 3 10.0
No 25 83.3 29 93.5 26 86.7 27 90.0
Comorbidity
Anxiety Disorder Yes 10 33.3 7 22.6 10 33.3 10 33.3
No 20 66.7 24 77.4 20 66.7 20 66.7
Depressive Disorder Yes 12 40.0 7 22.6 11 36.7 14 46.7
No 18 60.0 24 77.4 19 63.3 16 53.3
Substance Abuse Yes 6 20.1 6 19.5 6 20.1 2 6.7
No 24 80.0 25 80.6 24 80.0 28 93.3
History of Substance Dependence Yes 2 6.7 4 12.9 2 6.7 1 3.3
No 28 93.3 27 87.1 28 93.3 29 96.7
Axis II disorder Yes 7 23.3 5 16.1 4 13.3 8 26.7
No 23 76.7 26 83.9 26 86.7 22 73.3
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patients randomly allocated after waiting for treatment (N ¼ 44
standard CT, N ¼ 41 intensive CT). Second, sleep diaries completed
by the intensive CT group were analysed. A one-way repeated
measures ANOVA, and planned contrasts compared mean reported
sleep duration before, during and after intensive CT. Third, the
impact of the memory-updating procedure on sleep duration was
examined by comparing sleep duration reported in the diary before
and after the ﬁrst discrete period of memory-updating in intensive
CT, with sleep duration before and an equivalent amount of time
after a randomly selected pre-treatment day with no intervention
(Mean day ¼ 4.78, SD ¼ 2.75). Memory-updating was most
commonly done for the ﬁrst time on the second day of intensive
treatment (39.3% of patients). Updating was done between one and
four times (M ¼ 2.09, SD ¼ 1.04), and on average concluded on day
4 of treatment (M ¼ 4.12, SD ¼ 1.54).
To address Question 4 (impact of reduced sleep duration on
PTSD treatment outcome), correlation and regression analyses
examined the relationship between sleep duration at initial
assessment and end of treatment (14 weeks), and treatment
outcome (PDS at 14 and 40 weeks), controlling for PDS. This anal-
ysis included all 85 patients who received cognitive therapy,
including those who had initially been allocated to the waitlist. An
ANCOVA checked beforehand that there were no effects of type of
CT (intensive versus standard) or allocation (immediate versus
post-wait), nor an interaction, all p's > 0.32.
To investigate other measures that may be associated with
improvement in sleep duration in therapy, symptoms that were
hypothesised may be associated with sleep improvements were
explored (Question 5). ANCOVAs tested differences between con-
ditions (CT, EST, wait) for nightmares, hyperarousal symptoms
(CAPS, PDS), and patient-rated anxiety about going to bed at 14
weeks, controlling for baseline severity. In patients treatedwith CT-
PTSD, sleep duration change with treatment was correlated with
change in nightmares and hyperarousal symptoms (CAPS, PDS),
and anxiety about going to bed.
3. Results
3.1. Question 1: Do psychological therapies for PTSD improve self-
reported sleep?
3.1.1. Sleep duration
Fig. 1 illustrates the changes in reported sleep duration across
the assessment points for cognitive therapy, supportive therapy
and waitlist (see Table 2 for descriptive statistics). The ANCOVA
showed a signiﬁcant difference between the conditions, F(2,
117) ¼ 4.30, p ¼ 0.016, partial h2 ¼ 0.07. Cognitive therapy, but not
supportive therapy, led to greater improvement in sleep duration
than the waitlist control, baseline-adjusted differences (sleep
duration) for CT ¼ 0.73 (95% CI ¼ 0.20 to 1.26), p ¼ 0.008; and for
EST ¼ 0.21 (95% CI ¼ 0.41 to 0.82), p ¼ 0.51. Patients receiving CT
reported sleeping 55.2 min longer after treatment (14 weeks),
compared to 21.6 min longer with supportive therapy and 12.6 min
on the waitlist (see Table 2).
3.1.2. PTSD symptom severity (excluding sleep)
PTSD symptom changes are reported for comparison. Table 2
shows the changes in self-reported PTSD symptoms (excluding
sleep). The ANCOVA showed a signiﬁcant difference between the
conditions, F(2, 117) ¼ 40.40, p < 0.001, partial h2 ¼ 0.41. Both
treatments led to greater reductions in PTSD symptoms compared
to waitlist; baseline-adjusted differences for CT ¼ - 16.63 (95%
CI ¼ 12.95 to 20.31); EST ¼ 9.55 (95% CI ¼ 5.26 to 13.83).
3.1.3. Additional sleep measures
For self-reported sleep quality, the ANCOVA showed a signiﬁ-
cant difference between the conditions for self-reported sleep-
quality, F(2, 109) ¼ 12.77, p < 0.001, partial h2 ¼ 0.19. Cognitive
therapy led to greater changes in sleep quality than waitlist:
baseline-adjusted mean difference ¼ 26.54 (95% CI ¼ 16.11 to
36.98), p < 0.001, as did supportive therapy baseline-adjustedmean
difference ¼ 16.10 (95% CI ¼ 3.97 to 22.23), p ¼ 0.01.
For insomnia symptoms assessed with the PDS and CAPS, the
ANCOVAs showed signiﬁcant differences between the conditions:
PDS insomnia, F(2, 117) ¼ 15.84, p < 0.001, partial h2 ¼ 0.213; CAPS
insomnia, F(2, 117) ¼ 5.53, p ¼ 0.005, partial h2 ¼ 0.09. Cognitive
therapy led to greater changes in insomnia than waitlist: baseline-
adjustedmean difference for PDS insomnia¼1.12 (95% CI¼1.52
to 0.72), p < 0.001; CAPS insomnia ¼ 2.00 (95% CI ¼ 3.23
to 0.77), p ¼ 0.002. In contrast, supportive therapy was not su-
perior to the waitlist on CAPS insomnia severity, baseline adjusted
mean difference ¼ 0.86 (95% CI ¼ 2.30 to 0.58), p ¼ 0.24, but
showed advantages over the waitlist on PDS insomnia
severity ¼ 0.52 (95% CI ¼ 0.98 to 0.60), p ¼ 0.03.
Related-samples McNemar tests showed that with cognitive
therapy, p < 0.001, and supportive therapy, p ¼ 0.021, there was a
reduction in the proportion of patients with clinically signiﬁcant
insomnia symptoms between the initial and 14-week assessments,
but not in the waitlist group, p ¼ 0.69. At the 14-week assessment,
44.3% of patients who had received cognitive therapy and 63.3% of
those who had received supportive therapy continued to report
clinically signiﬁcant insomnia symptoms, according to the CAPS.
3.2. Question 2: Does the degree of sleep change depend on whether
the intervention is trauma or non-trauma-focused?
3.2.1. Sleep duration
The ANCOVA across all assessment points showed a signiﬁcant
effect of treatment condition F(1, 112) ¼ 6.50, p ¼ 0.012, partial
h2 ¼ 0.06. Cognitive therapy led to greater improvement in sleep
duration than supportive therapy, baseline-adjusted mean
difference ¼ 0.60 (95% CI ¼ 0.13 to 1.06) (see Fig. 1 and Table 2).
3.2.2. PTSD symptom severity (excluding sleep)
The ANCOVA for PTSD symptoms without sleep showed a sig-
niﬁcant difference between the conditions, F(1, 112) ¼ 11.99,
p < 0.001, partial h2 ¼ 0.10. Cognitive therapy led to greater
improvement in PTSD symptoms than supportive therapy,
baseline-adjusted mean difference ¼ 6.54 (95% CI ¼ 2.80
to 10.27).
3.2.3. Additional sleep measures
For sleep quality, there was a trend for cognitive therapy to be
superior to supportive therapy: baseline-adjusted mean
difference ¼ 8.72 (95% CI ¼ 1.35 to 18.79), p ¼ 0.089. Cognitive
therapy was superior to supportive therapy on PDS insomnia
severity¼ 0.64 (95% CI ¼1.07 to0.25), p¼ 0.001, and for CAPS
insomnia severity ¼ 1.22 (95% CI ¼ 2.40 to 0.04), p ¼ 0.043.
3.3. Question 3: Does the memory-updating procedure in CT-PTSD
facilitate sleep improvements?
3.3.1. Comparison of intensive and weekly cognitive therapy at 3
weeks
3.3.1.1. Sleep duration. The ANCOVA showed a signiﬁcant effect of
group (see Table 2), F(1, 82) ¼ 5.75, p ¼ 0.019, partial h2 ¼ 0.07 on
sleep duration at week 3. Patients receiving intensive cognitive
therapy, who had completed the updating memory-updating
intervention at this stage, reported sleeping longer than those
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receiving standard CT, who had not yet updated their memories,
baseline-adjusted mean difference ¼ 0.67 (95% CI ¼ 0.11 to 1.22).
3.3.1.2. PTSD symptom severity (excluding sleep). The ANCOVA
showed a signiﬁcant effect of group (see Table 2), F(1, 82) ¼ 11.65,
p ¼ .001, partial h2 ¼ .124. Patients receiving intensive therapy
reported fewer PTSD symptoms at 3 weeks, than those receiving
standard cognitive therapy, baseline-adjusted mean difference ¼
-6.93 (95% CI ¼ -2.89 to -10.97).
3.3.2. Analysis of sleep diaries in intensive cognitive therapy: before
and after memory updating intervention
Table 2 shows the mean sleep duration for pre, during and post
intensive cognitive therapy as assessed with the sleep diary. The
ANOVA showed a signiﬁcant effect of time on self-reported sleep
duration, F(2, 44) ¼ 8.68, p ¼ 0.001, partial h2 ¼ 0.28. There was a
signiﬁcant linear trend across the three time points F(1, 22)¼ 10.27,
p¼ 0.004. Planned contrasts showed signiﬁcant differences in sleep
duration between the pre and post-treatment sleep diaries, F(1,
22) ¼ 10.27, p ¼ 0.004, partial h2 ¼ 0.32; and between during-
treatment and post-treatment diaries, F(1, 23) ¼ 7.52, p ¼ 0.01,
partial h2 ¼ 0.25. There was also a trend for a difference between
pre and during-treatment sleep diaries, F(1, 28) ¼ 4.13, p ¼ 0.05,
partial h2 ¼ 0.13. Parallel to the results of the questionnaire re-
ported sleep duration, patients receiving intensive therapy re-
ported in the diary an increase in sleep duration of about an hour
with therapy (see Table 2 and Fig. 2).
Table 3 shows the comparison of sleep duration reported for the
nights before and after memory-updating in therapy. There was a
signiﬁcant increase of 41.04 min of self-reported sleep duration
from the night before updating to after updating, t(23) ¼ 2.46,
p ¼ 0.022, partial h2 ¼ 0.21, whereas there was no signiﬁcant
change in sleep duration from the night before a randomly selected
pre-treatment day to an equivalent period afterwards (with no
intervention), t(23) ¼ 0.270, p ¼ 0.79, partial h2 ¼ 0.003.
3.4. Question 4: What is the effect of sleep duration on PTSD
treatment outcome?
For patients receiving CT-PTSD, shorter sleep duration at base-
line correlated with higher PTSD symptom severity (PDS excluding
sleep) at baseline, r ¼ 0.48 p < 0.001; post-treatment (14 weeks),
r¼0.23, p¼ 0.007; and at 40-week follow-up, r¼0.24, p¼ 0.03.
However, regression analyses showed that shorter sleep duration at
baseline did not predict PTSD severity at 14 weeks, ß ¼ 0.12,
p ¼ 0.30, and 40 weeks, ß ¼ 0.07, p ¼ 0.55, over and above what
could be predicted from initial PDS scores (excluding sleep). Simi-
larly, poor sleep at the end of treatment correlated with PTSD
severity (PDS excluding sleep) at 40-week follow-up, r ¼ 0.31,
p ¼ 0.003, but regression analysis showed that it did not predict
PTSD symptoms over and above PTSD severity at the end of treat-
ment, ß ¼ 0.07, p ¼ 0.32. This shows that sleep duration at
baseline and end of treatment did not predict PTSD treatment
outcome over and above what could be predicted by PTSD symp-
tom severity.
Change in sleep duration from baseline to end of treatment,
however, predicted PTSD severity at the end of treatment over and
above initial PTSD symptom severity, ß ¼ 0.22, p ¼ 0.031.
3.5. Question 5: Symptoms that may be associated with sleep
improvement
The ANCOVAs showed signiﬁcant differences at 14 weeks be-
tween conditions for: PDS nightmares, F(2, 117) ¼ 11.09, p < 0.001,
partial h2 ¼ 0.159; CAPS nightmares, F(2, 117) ¼ 10.22, p < 0.001,
partial h2 ¼ 0.149; PDS arousal symptoms (excluding sleep), F(2,
117) ¼ 31.79, p < 0.001, partial h2 ¼ 0.35; CAPS arousal symptoms
(excluding sleep), F(2, 117) ¼ 21.41, p < 0.001, partial h2 ¼ 0.27; and
anxiety about going to bed, F(2, 117) ¼ 5.17, p ¼ 0.007, partial
h2 ¼ 0.081. Cognitive therapy led to larger improvements than the
waitlist on each of these measures: baseline-adjusted mean dif-
ference for PDS nightmares ¼ 0.75 (95% CI ¼ 1.08 to 0.42),
Fig. 1. Mean hours of sleep (and standard error bars) reported by patients receiving cognitive therapy (CT; standard and intensive combined, immediate allocations only), emotion-
focused supportive therapy (EST) and waitlist.
E. Woodward et al. / Behaviour Research and Therapy 97 (2017) 75e8580
p < 0.001; CAPS nightmares ¼ 2.07 (95% CI ¼ 3.00 to 1.15),
p < 0.001; PDS arousal symptoms (excluding sleep) ¼ - 1.23 (95%
CI ¼1.53 to0.92), p < 0.001; CAPS arousal symptoms (excluding
sleep)¼9.91 (95% CI¼12.92 to6.90), p < 0.001; anxiety about
going to bed ¼ 16.19 (95% CI ¼ 28.85 to 3.53, p < 0.001. In
contrast, supportive therapy was only superior to the waitlist on
arousal, PDS arousal ¼ 0.74 (95% CI ¼ 1.09 to 0.39), p < 0.001;
CAPS arousal ¼ 5.96 (95% CI ¼ 9.44 to 2.48), p < 0.001.
Cognitive therapy was superior to supportive therapy on all mea-
sures: PDS nightmares ¼ 0.48 (95% CI ¼ 0.81 to 0.15),
p ¼ 0.005; CAPS nightmares ¼ 1.11 (95% CI ¼ 2.02 to 0.178),
p ¼ 0.02; PDS arousal symptoms (excluding sleep) ¼ - 0.48 (95%
Table 2
Mean and standard deviations (SD) at each assessment point for the psychological treatment and waitlist conditions, and for intensive and standard cognitive therapy
(including those initially allocated to the waitlist).
Cognitive Therapy
(CT) (N ¼ 61)
Supportive Therapy
(N ¼ 30)
Waitlist (N ¼ 30) Intensive CT,
including post-wait
(N ¼ 41)
Standard CT,
including post-wait
(N ¼ 44)
Hours of Sleep
Mean SD Mean SD Mean SD Mean SD Mean SD
Baseline 5.16 1.53 5.35 1.54 5.15 1.48 5.13 1.53 5.38 1.69
3 weeks 5.86 1.77 5.62 1.14 e e 6.11 1.59 5.62 1.84
6 weeks 5.97 1.77 5.53 1.03 5.23 1.56 5.95 1.86 5.98 1.66
14 weeks 6.08 2.05 5.71 1.12 5.36 1.66 6.03 1.66 6.31 2.23
27 weeks 6.07 1.78 5.61 1.42 e e 5.88 1.72 6.42 1.71
40 weeks 6.14 1.72 5.53 1.54 e e 6.08 1.78 6.51 1.85
Sleep Diary Data: Hours of Sleep
Pre-treat e e e e e e 5.43 1.44 e e
During treat e e e e e e 5.62 1.34 e e
Post-treat e e e e e e 6.43 1.73 e e
PTSD Severity (excluding sleep)
Baseline 30.69 6.79 32.11 6.93 30.05 7.33 30.69 6.94 29.74 7.01
3 weeks 18.59 10.27 26.43 11.48 e e 16.21 8.90 22.67 10.51
6 weeks 14.53 9.56 21.73 12.33 29.76 6.86 13.86 8.41 16.80 11.71
14 weeks 9.75 9.51 18.40 13.03 27.04 9.02 10.77 8.60 8.73 9.66
27 weeks 11.01 11.01 17.37 12.06 e e 11.82 10.01 8.81 10.31
40 weeks 10.45 10.80 19.38 13.96 e e 12.17 10.98 9.56 10.35
Further measures at Baseline and 14 Weeks
Sleep Quality
Baseline 34.82 21.30 31.07 20.61 36.07 19.69 35.85 20.25 33.08 20.64
14 weeks 58.95 27.33 46.61 26.81 33.04 16.74 57.56 31.03 56.79 23.60
Insomnia item (PDS)
Baseline 1.98 1.01 2.15 0.88 2.40 0.72 1.98 0.98 2.17 0.92
14 weeks 0.89 1.05 1.57 0.97 2.20 0.85 0.80 1.18 0.99 0.99
Insomnia item (CAPS)
Baseline 5.48 2.43 6.05 1.83 5.08 2.22 5.11 2.38 5.40 2.62
14 weeks 2.99 3.23 4.50 3.33 4.73 2.66 2.63 3.27 3.01 3.04
Insomnia item (CAPS, percent and N meeting clinical cut-off)
Baseline 78.7% 48/61 90.0% 27/30 76.7% 23/30 78.0% 32/41 75.0% 33/44
14 weeks 44.3% 27/61 63.3% 19/30 70.0% 21/30 46.3% 19/41 36.4% 16/44
Bad dreams and nightmares (PDS)
Baseline 1.57 0.96 1.53 0.86 1.53 0.94 1.43 0.93 1.51 1.05
14 weeks 0.43 0.67 0.90 0.99 1.17 0.96 0.42 0.72 0.46 0.74
Bad dreams and nightmares (CAPS)
Baseline 3.75 2.60 3.42 2.61 3.27 2.70 3.33 2.62 3.82 2.63
14 weeks 1.31 2.13 2.27 2.72 3.17 2.62 1.27 2.14 1.29 2.12
Hyperarousal (excluding sleep, PDS)
Baseline 2.09 0.58 2.15 0.54 2.05 0.60 2.05 0.60 2.14 0.53
14 weeks 0.80 0.74 1.32 0.86 2.00 0.74 0.74 0.75 0.93 0.68
Hyperarousal (excluding sleep, CAPS)
Baseline 18.29 5.16 18.55 4.62 17.00 5.74 17.47 4.18 19.18 5.97
14 weeks 8.26 7.69 12.28 7.34 17.43 6.28 7.69 7.75 9.49 7.48
Anxiety going to bed
Baseline 42.54 30.59 33.67 27.98 46.33 26.45 39.43 32.46 41.71 26.45
14 weeks 20.98 30.04 35.17 31.83 38.50 29.04 17.72 25.60 22.56 30.23
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CI¼0.79 to0.18), p¼ 0.002; CAPS arousal symptoms (excluding
sleep) ¼ 3.95 (95% CI ¼ 6.94 to 0.96), p ¼ 0.010; anxiety about
going to bed ¼ 17.29 (95% CI ¼ 30.03; 4.55), p ¼ 0.008.
For participants treated with cognitive therapy (N ¼ 85), change
in the frequency of nightmares correlated with changes in sleep
duration; PDS nightmares r ¼ 0.32, p ¼ 0.003; CAPS nightmares,
r ¼ 0.26, p ¼ 0.018, as did change in hyperarousal symptoms
(excluding sleep); PDS arousal r ¼ 0.21, p ¼ 0.056, CAPS arousal
r ¼ 0.388, p < 0.001, and change in anxiety about going to bed,
r ¼ 0.345, p ¼ 0.001. This shows that sleep duration improvements
were correlated with improvements in nightmares, arousal and
anxiety about going to bed.
4. Discussion
The present study investigated changes in self-reported sleep
with psychological treatments for PTSD. Speciﬁcally, it was inves-
tigated whether 1) psychological therapies for PTSD lead to an
improvement in sleep compared to a waitlist condition; 2) the
improvement in sleep depends on whether the intervention is
trauma or non-trauma-focused; 3) improvements in sleep are
related to memory-updating interventions in CT-PTSD; 4) initial
sleep duration affects PTSD treatment outcome; and explored 5)
whether improvements in hyperarousal, nightmares and anxiety
about going to bed are associated with sleep duration
improvements.
The results showed that CT-PTSD, but not supportive therapy,
led to greater improvement in self-reported sleep duration in
comparison to a waitlist control group (Question 1). Among the
additional sleep measures, the same pattern was observed for
assessor-rated insomnia symptoms (CAPS). For sleep quality and
self-reported insomnia symptoms (PDS) both CT-PTSD and sup-
portive therapy were superior to the waitlist. Direct comparisons
between the two treatment conditions (Question 2) showed that
cognitive therapy lead to greater improvement than supportive
therapy in sleep duration and insomnia symptoms (CAPS, PDS),
with a trend for superiority on sleep quality. This suggests that
trauma-focused therapy is more effective than non-trauma-
focused therapy for improving insomnia symptoms in PTSD. Sleep
duration increased by nearly one hour on average with CT-PTSD,
which focuses on re-processing threatening meanings of the
trauma and updating traumamemories with the revised meanings,
compared to around 20 minutes with supportive therapy, which
was nontrauma-focused. More people had residual insomnia on the
CAPS after supportive therapy, than after CT-PTSD. The pattern of
results suggests that the sleep changes with CT-PTSD were speciﬁc
effects of the intervention, rather than effects of the passage of time
or non-speciﬁc effects of therapy. This conclusion is further sup-
ported by the ﬁnding that for patients receiving intensive CT, the
improvement in sleep duration had already occurred by the 3-week
assessment, and that sleep diaries showed a signiﬁcant increase in
sleep duration during theweek of intensive treatment (Question 3).
These ﬁndings suggest that sleep improves with trauma-focused
CT, where trauma memories are linked with updating informa-
tion. This is consistent with a recent paper showing that sleep
duration improved by an average of one hour with weekly CT-PTSD
in a large sample of PTSD patients in a routine clinical service
(Lommen et al., 2015), and with studies showing an improvement
in sleep duration after trauma-focused therapies; cognitive
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Fig. 2. Sleep diary data: Mean sleep duration (with standard error bars) during the 7- day treatment phase of intensive Cognitive Therapy for PTSD. Pre ¼ the mean sleep duration
reported in the pre-treatment sleep diary given for comparison. Eve ¼ sleep duration that night (Eve 1 would be evening 1 of day 1 of intensive therapy).
Table 3
Mean sleep duration (hours) and standard deviations before and after memory-
updating during intensive Cognitive Therapy for PTSD, and before and after no
updating (or intervention).
Updating (n ¼ 24) No Updating
(n ¼ 24)
Mean SD Mean SD
Pre updating 5.14 1.96 5.52 1.95
Post updating 5.82 2.27 5.40 1.73
Change (in hours) 0.68*** 1.36 0.12 2.23
Note. *** ¼ p < 0.001.
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processing therapy and prolonged exposure therapy (Galovski
et al., 2009; Gutner et al., 2013). The reported gain of one hour of
sleep in CT-PTSD is similar to that observed in successful insomnia
treatment with insomnia patients (see Mitchell, Gehrman, Perlis, &
Umscheid, 2012), which is encouraging. Sleep quality and insomnia
improvements with trauma-focused treatment in the present study
are consistent with previous studies showing that CBT for PTSD
improves insomnia symptoms in PTSD patients (e.g., Gutner et al.,
2013). However, by post-treatment (14 weeks), patients’ reported
sleep duration was only six hours on average, which is lower than
the recommended 7e9 h for adults (see Hirshkowitz et al., 2015).
Furthermore, 43.3% of patients were assessed as continuing to
experience clinically signiﬁcant insomnia symptoms (CAPS) after
CT-PTSD. This is consistent with the ﬁndings of previous studies
that insomnia is commonly residual after CBT for PTSD (Zayfert &
DeViva, 2004). Overall these ﬁndings suggest that self-reported
sleep duration, quality and insomnia symptoms (difﬁculties fall-
ing and staying asleep) are improved with trauma-focused CT for
PTSD, but that insomnia remains residual for up to half of patients
after therapy.
The design of the present study allowed for a closer examination
of a core procedure (memory-updating) in CT-PTSD that may be
important for facilitating sleep duration improvements with PTSD
therapy (Question 3). Patients in the intensive CT group reported
around a 40-min increase in sleep duration after memory-updating
in therapy, whereas there was no change in sleep duration after an
equivalent recording period before therapy, where no intervention
was done. This suggests that memory-updating may be associated
with the sleep duration improvements seen with CT-PTSD. This
ﬁnding is in line with a previous study that found an increase in
objective sleep duration after processing trauma memories with
written narrative exposure (Kobayashi, Mellman, Altaee, Howell, &
Lavela, 2016). However, in order to conclude that the memory
updating intervention in CT-PTSD facilitated sleep improvements,
memory updating would need to be compared to an alternative
active intervention in CT-PTSD, carried out at the same point in
therapy, but that did not include memory-updating. Future studies
could investigate this.
The study found that initial sleep duration was not an inde-
pendent predictor of PTSD treatment response over and above
PTSD symptom severity (Question 4), suggesting that reduced sleep
duration may not interfere with PTSD treatment outcome. This is
consistent with Lommen and colleagues’ (2015) recent study,
which found that reduced sleep duration did not interfere with the
overall efﬁcacy of CT-PTSD. Concerns for the effects of sleep dis-
turbances in PTSD treatment may come in part from experimental
studies with healthy controls, where variables of interest were
often measured after full sleep deprivation rather than sleep
disturbance or reduction. The results of the current study raise the
possibility that reduced sleep duration may have a less severe
impact than total sleep deprivation on factors important in cogni-
tive therapy, such as emotional and cognitive processing. This
ﬁnding is encouraging as it suggests that PTSD therapy can still be
effective in the presence of reduced sleep duration, but does not
preclude the possibility that sleep-focused treatment, before PTSD
therapy could further enhance treatment gains. The ﬁnding that
changes in sleep duration predicted posttreatment PTSD symptoms
over and above initial symptom severity indicates greater treat-
ment gains in patients whose sleep improved with treatment. A
recent study found that sleep impairment improvements with
sleep-directed hypnosis before PTSD therapy did not augment PTSD
treatment gains (Galovski et al., 2016), however the effects of sleep
treatments such as CBT for insomnia, have not yet been investi-
gated, and may yield different results.
The present study also explored symptoms that may be
associated with sleep improvements with CT-PTSD, by examining
whether arousal, nightmares and pre-bed anxiety were affected by
treatment, and whether changes were associated with sleep
duration improvements (Question 5). The direction of effects be-
tween sleep improvement and improvements in nightmares,
arousal and pre-bed anxiety were not determined in this study.
However, the results, particularly differences in the effects of
trauma and non-trauma-focused psychotherapy, generate some
interesting hypotheses about how CT-PTSD may improve sleep
duration, based on previously proposedmechanisms of therapeutic
change with CT-PTSD (Ehlers et al., 2005).
There are several proposed mechanisms of PTSD symptom
change with CT-PTSD (Ehlers et al., 2005). The ﬁrst is a change in
the trauma memory, through elaborating and updating the trauma
memory with newmeanings. In the current study, one possibility is
that change in the trauma memory could have affected sleep
duration through reducing both daytime and night-time intrusive
memories and nightmares, and reducing hypervigilance and hy-
perarousal, and an overall sense of current threat. The results of the
present study were consistent with this interpretation, as only CT-
PTSD led to a greater reduction in nightmares than the waitlist, and
nightmare and hyperarousal reduction with CT-PTSD were associ-
ated with improvements in sleep duration. For hyperarousal
symptoms, supportive therapy also led to greater changes than the
waitlist, possibly suggesting that a reduction in hyperarousal may
be a less speciﬁc pathway to sleep duration improvements in pa-
tients with PTSD, than a reduction in nightmares. This would need
to be explored in further research.
The second proposed pathway of PTSD symptom change with
CT-PTSD is change in cognitive appraisals and related behaviours
(Ehlers et al., 2005). Another possibility is that change in appraisals
with CT-PTSD, including modifying appraisals of the need for vig-
ilance, the safety of the bedroom and of the individual when they
sleep, could theoretically increase sleep duration as a result of
reduced pre-sleep hypervigilance, hyperarousal, and avoidance of
the bed and sleep. The results of the present study may be
consistent with this suggestion, as a reduction in anxiety about
going to bedwas only foundwith CT-PTSD, and not with supportive
therapy, and was associated with sleep duration increases. How-
ever, the direction of effects between anxiety and sleep were not
determined, and it is plausible that sleep duration improvements
may lead to reduced anxiety about going to bed.
The ﬁnding that CT-PTSD but not supportive therapy led to
greater improvements compared to the waitlist in anxiety about
going to bed and nightmares, may help to explain why only CT-
PTSD led to sleep duration and clinician assessed insomnia im-
provements compared to thewaitlist, whereas both therapies led to
greater PTSD symptom improvements than the waitlist. It is
possible that improvements in these speciﬁc symptoms supported
increase in sleep duration and reduction in insomnia symptoms.
More research is required to look at how reductions in re-
experiencing, hyperarousal, and appraisal modiﬁcation may relate
to sleep improvements with CT-PTSD, and to determine the di-
rection of effects, by exploring the temporal precedence of these
PTSD symptom changes and their association with sleep
improvements.
4.1. Limitations and future directions
The present study has a number of limitations. First, the sleep
measure available regularly for all groups, at every time point, was
self-reported average sleep duration for the previous week, rather
than a validated self-report measure of sleep disturbances, or a
measure assessing the broad range of sleep disturbances found in
PTSD. However, sleep duration provided a useful indicator of sleep
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change with CT-PTSD, and improvements were also evidenced in
sleep quality ratings and self-reported and clinician assessed
insomnia symptoms and nightmares, suggesting that CT-PTSD also
had beneﬁcial effects on a broader range of sleep outcomes.
Furthermore, objective measures of sleep duration were also not
available. Some studies have shown that PTSD patients’ sleep diary
reports of sleep duration are often consistent with actigraphy
(Kobayashi, Huntley, Lavela, &Mellman, 2012), however it remains
unknown whether CT-PTSD also has a beneﬁcial effect on objec-
tively measured sleep. Second, it is conceivable that the use of sleep
diaries may have had a therapeutic effect on sleep symptoms in the
intensive CT group, as daily self-monitoring of sleep before treat-
ment may have a small beneﬁcial effect on self-reported sleep
(Talbot et al., 2014). However, this appears unlikely in the present
study, as the standard CT group showed similar gains in sleep
duration as the intensive CT group. Finally, as previously noted,
memory updating was compared to no intervention rather than an
alternative active intervention in CT-PTSD, which limits the con-
clusions that can be drawn from this ﬁnding. Further research
should address these limitations, and investigate whether change
in sleep with CT-PTSD is also reﬂected in objective data. Detailed
sleep diaries meeting the recommendations for standardised pro-
spective sleep self-monitoring (Carney et al., 2012) are also
required, to assess variables such as sleep onset latency and wake
time after sleep onset. Future studies could also further examine
the mechanisms of improvements in sleep duration in trauma-
focused CBT, and examine the speciﬁc effects of memory updat-
ing interventions in CT-PTSD by comparing memory updating to a
different active intervention in CT-PTSD.
Overall, this study shows that self-reported sleep and insomnia
symptoms improved with trauma-focused therapy for PTSD, and
that sleep duration improved faster when PTSD treatment was
delivered intensively over seven days. The results suggest that
updating the trauma memory, a key procedure of CT-PTSD, was
associated with sleep duration increase, although speciﬁc effects of
memory updating were not determined. CT-PTSD may affect sleep
duration through associated reductions in hyperarousal symptoms,
nightmares, and pre-bed anxiety. Initial sleep duration did not
predict PTSD treatment outcome, suggesting that CT-PTSD can be
effective in the presence of reduced pre-treatment sleep duration.
For many patients sleep difﬁculties were residual after PTSD
treatment, raising the possibility that sleep treatment preceding or
following PTSD treatment could enhance sleep gains and perhaps
also PTSD treatment gains.
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